Effectiveness of sofpironium bromaide gel for clozapine-induced hypersalivation in patients with treatment-ressistant schizophrenia:A double-blind comparative study (Effectiveness of ECCLOCKgel for clozapine-induced hypersalivation)

开始日期2021-07-17

申办/合作机构-

100 项与 Sofpironium Bromide 相关的临床结果

登录后查看更多信息

100 项与 Sofpironium Bromide 相关的转化医学

登录后查看更多信息

100 项与 Sofpironium Bromide 相关的专利（医药）

登录后查看更多信息

项与 Sofpironium Bromide 相关的文献（医药）

2024-01-01·The Journal of dermatology

Efficacy of 5% sofpironium bromide gel in Duchenne muscular dystrophy with palmoplantar hyperhidrosis: A retrospective case study

Article

作者: Iimoto, Masami ; Funato, Michinori ; Iwata, Reina

Abstract:

Duchenne muscular dystrophy (DMD) is a severe, progressive, muscle‐wasting disease. Notably, several extramuscular manifestations and complications of advanced DMD, including skin disorders, are known. However, hyperhidrosis and its treatment have not been well‐described in association with advanced DMD, therefore we aimed to confirm the efficacy of 5% sofpironium bromide gel in treating secondary hyperhidrosis in patients with advanced DMD. We retrospectively reviewed patients with advanced DMD who underwent treatment with 5% sofpironium bromide gel. All patients were evaluated using the hyperhidrosis disease severity scale (HDSS) score and by measuring the gravimetric weight of palmar and/or plantar sweat. Three patients with advanced DMD were treated and the patients were aged 28, 31, and 32 years, respectively. Their HDSS scores showed a decreasing tendency within 5 weeks after treatment. In addition, all patients had a decreased gravimetric weight of palmar and/or plantar sweat, and the mean decrease rate of palmar sweat at 7 weeks after treatment was 53.7%. One patient had skin dryness on both soles, but no serious adverse events were observed. Treatment using 5% sofpironium bromide gel showed beneficial efficacy against palmoplantar hyperhidrosis in patients with advanced DMD. These findings warrant further investigation in future studies.

2023-01-01·BJPsych open

Efficacy of sofpironium bromide gel on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: double-blind, controlled crossover study

Article

作者: Shioiri, Toshiki ; Amano, Koichi ; Amano, Yuhei ; Mazda, Jun ; Ohi, Kazutaka

Background:

Hypersalivation is a major side-effect of clozapine in patients with treatment-resistant schizophrenia.

Aims:

We investigated the efficacy of topical anticholinergic formulation sofpironium bromide gel for improving hypersalivation in patients with treatment-resistant schizophrenia receiving clozapine.

Method:

A double-blind, controlled crossover study was conducted with sofpironium bromide gel and a placebo gel to treat clozapine-induced hypersalivation in 16 patients with treatment-resistant schizophrenia. Patients were randomly divided between groups A and B (each n = 8). Group A was treated with sofpironium bromide gel for 6 weeks, followed by a 2-week washout period and 6 weeks of placebo gel, after which they were observed for another 2 weeks. In contrast, group B was treated with placebo gel for 6 weeks, followed by a 2-week washout period, 6 weeks of sofpironium bromide gel and a 2-week observation period. One-minute saliva volume, objective salivation ratings (Drooling Severity and Frequency Scale and Nocturnal Hypersalivation Rating Scale) and subjective salivation ratings (Visual Analogue Scale) were assessed every 2 weeks.

Results:

All patients completed the trials. Three patients reported mild, spontaneously resolved skin itching. Compared with baseline values, the 1-min saliva volumes of both groups were significantly decreased by approximately 30% at the second week of sofpironium bromide gel treatment (P < 0.001), and significantly decreased by >40% at the fourth and sixth weeks of treatment (P < 0.001). The effects were maintained for over 2 weeks even after the treatment was discontinued.

Conclusions:

We suggest that sofpironium bromide gel is effective in treating clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia.

2022-12-01·Dermatology and therapy

Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics

Review

作者: Adlam, Taylor M ; Potts, Geoffrey A ; Farshchian, Mehdi ; Wong, Nikita S

BACKGROUND:

Topical anticholinergics have been reported to be effective in managing hyperhidrosis (HH) given the recent approval of glycopyrronium tosylate.

OBJECTIVE:

This review aimed to examine the effectiveness of emerging topical anticholinergic treatments for HH and their associated adverse effects in comparison to current treatment options.

METHODS:

We conducted a search within the PubMed and Embase databases for current and emerging topical anticholinergic treatments for primary HH.

RESULTS:

The topical anticholinergics that have been recently investigated for use in HH include glycopyrrolate, oxybutynin, sofpironium bromide, and umeclidinium. The only agent currently FDA approved is glycopyrrolate.

CONCLUSION:

Knowledge of topical anticholinergic treatment options is important for patient care when managing HH. This review shows that while available safety data thus far are limited, emerging topical anticholinergics pose minimal known human risks.

项与 Sofpironium Bromide 相关的新闻（医药）

2024-06-20

·药明康德

85%患者获得缓解！FDA批准创新小分子疗法上市

▎药明康德内容团队编辑 Botanix Pharmaceuticals公司今日宣布，美国FDA已经批准Sofdra（sofpironium）凝胶（12.45%）上市，用于治疗9岁以上的儿童和成人原发性腋窝多汗症患者。新闻稿指出，这是FDA批准治疗这一症状的首款新分子实体。 FDA的批准得到两项关键性3期临床试验结果的支持，包括701名原发性腋窝多汗症患者。试验结果显示，约85%患者在使用sofpironium凝胶后病情出现具临床意义的改善。两项3期临床试验均达到了所有主要终点和关键性次要终点。 Sofpironium是一种抗胆碱能/抗毒蕈碱药物，通过与受体结合阻断出汗信号，从而抑制腺体出汗。该疗法设计为使用专有涂抹器将sofpironium以凝胶制剂的形式递送至腋下，使患者避免直接接触手上的药物。多汗症患者分泌超过调节体温所需的汗液，这是一种对患者生活质量产生深远影响的症状，它可能影响患者的工作生产力、精神健康、个人关系和日常活动。在粉刺和特应性皮炎之后，多汗症是第三大皮肤症状，仅在美国，就有约1000万患者受到原发性腋窝多汗症的困扰。了解更多FDA获批新药请点击下图访问我们的小程序 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] FDA approval of Sofdra – the first new drug for primary axillary hyperhidrosis. Retrieved June 20, 2024, from https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02819259-6A1212299 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期上市批准

2024-06-20

·Pharmaceutical Technology

Botanix’s hyperhidrosis treatment Sofdra gains FDA approval

The treatment is indicated for usage in adults and children aged nine years and above. Credit: BongkarnGraphic / Shutterstock. Botanix Pharmaceuticals has announced the receipt of approval from the US Food and Drug Administration (FDA) for Sofdra (sofpironium) gel, 12.45%, for excessive underarm sweating (primary axillary hyperhidrosis). The treatment is indicated for usage in adults and children aged nine years and above. Sofdra is the first and only new chemical entity to receive approval in the US for this condition. The FDA’s decision was based on the results from the two Phase III CARDIGAN studies in 701 patients. The trials assessed the efficacy and safety of Sofdra versus vehicle in primary axillary hyperhidrosis patients. See Also: SGNB-7H4V by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval SGNB-7H4V by Pfizer for Epithelial Ovarian Cancer: Likelihood of Approval Sofdra met all primary and secondary endpoints, demonstrating significant changes from baseline in Gravimetric Sweat Production (GSP) and the Hyperhidrosis Disease Severity Measure-Axillary, 7-item (HDSM-AX7) score. Botanix will commence an early patient experience programme in the third quarter (Q3) of 2024, allowing qualified patients to obtain early access to Sofdra. This programme will support patients through telemedicine and the payer reimbursement process, making them the first to use Sofdra commercially. A broader launch is anticipated in early Q4 2024. Botanix CEO Dr Howie McKibbon stated: “We are pleased to share this accomplishment with our dedicated Botanix team and dermatologist partners, patients who participated in the clinical studies and our shareholders who made this approval possible. “This is a transformative event for Botanix as we transition from a development stage to a revenue-generating dermatology company.” Botanix executive chairman Vince Ippolito stated: “We are very excited to provide a new option for the 10 million patients with primary axillary hyperhidrosis in the United States.” “As the first and only new chemical entity, Sofdra represents a new therapeutic approach for dermatologists to treat patients with this disabling medical condition.”

临床结果临床3期上市批准

2024-06-01

·药明康德

6月7款创新药有望获FDA批准

▎药明康德内容团队编辑根据PDUFA的预期目标日期，预计6月，美国FDA将对7款创新药物的批准做出监管决定，本文将对这些疗法进行相关介绍。▲6月有望在美国获批的新药（药明康德内容团队制图，点击可见大图）活性成分：Elafibranor适应症：原发性胆汁性胆管炎（PBC）公司名称：Ipsen/GenfitElafibranor是一种每日一次、口服、潜在“first-in-class"的双重过氧化物酶体激活受体（PPAR）α/δ激动剂。新闻稿指出，elafibranor有望成为近十年来治疗罕见胆汁淤积性肝病PBC的首款新型二线疗法。该申请已被授予优先审评资格，PDUFA目标日期为2024年6月10日。Elafibranor的关键性3期试验ELATIVE的积极结果显示，患者在各关键终点的疾病进展生物标志物上均出现具有统计学意义的改善，主要复合终点达到显著治疗获益。80 mg elafibranor组（51%）达到生化应答的患者与安慰剂组（4%）相比的差异为47%（P<0.001）。安全性方面，elafibranor的耐受性良好，所显示的安全性特征与既往试验一致。图片来源：123RF活性成分：Imetelstat适应症：患有骨髓增生异常综合征的输血依赖性贫血患者公司名称：GeronImetelstat是Geron公司开发用于治疗血液癌症的潜在“first-in-class”端粒酶抑制剂。该疗法可以抑制癌变干细胞和祖细胞不可控制的增殖，导致癌变细胞的凋亡，具有改变疾病进程的活性。今年3月，美国FDA肿瘤学药物咨询委员会（ODAC）以12比2的投票结果，支持imetelstat用于治疗对红细胞生成刺激剂（ESAs）无应答或产生耐药，或无法接受ESAs的输血依赖性贫血成年患者，这些患者患有低风险骨髓增生异常综合征。Imetelstat被行业媒体Evaluate列为今年有望获批的10大潜在重磅疗法之一。ODAC的支持主要基于IMerge临床3期试验结果。该试验的主要终点为至少连续8周的输血独立性（RBC-TI），imetelstat与安慰剂相比显著提高达到主要终点的患者比例（p<0.001）。对imetelstat产生应答的患者中位RBC-TI持续时间接近一年。活性成分：21价肺炎球菌结合疫苗适应症：预防侵袭性肺炎球菌疾病和肺炎球菌肺炎公司名称：默沙东默沙东的在研21价肺炎球菌结合疫苗（V116）专门设计用于预防主要导致成人肺炎球菌疾病的肺炎链球菌血清型，包括8种独特的血清型。V116设计为单剂给药，有助于预防成人侵袭性肺炎球菌疾病和肺炎球菌肺炎。该疫苗获FDA授予优先审评资格。根据新闻稿，如若获批，V116将成为首个专门为成人设计的肺炎球菌结合疫苗。该疫苗的上市申请主要基于关键3期试验STRIDE-3的数据。该试验主要终点的分析显示，根据第30天血清型特异性调理吞噬活性（OPA）几何平均滴度（GMTs）的测量结果，在50岁及以上成人（队列1）中，V116与活性对照疫苗共有的所有10种血清型中，V116引起的免疫应答呈现非劣效性。根据第30天OPA GMT的测定结果以及从第1天至第30天OPA升高≥4倍的患者比例，V116中包含的其中11种血清型中有10种展现良好的免疫应答，活性对照疫苗不包含这11种血清型。活性成分：Sofpironium bromide适应症：原发性腋窝多汗症公司名称：Botanix PharmaceuticalsSofpironium bromide是一种抗胆碱能/抗毒蕈碱药物，通过与受体结合阻断出汗信号，从而抑制腺体出汗。该疗法设计为使用专有涂抹器将sofpironium bromide以凝胶制剂的形式递送至腋下，使患者避免直接接触手上的药物。在3期试验当中，约85%患者在使用15% sofpironium bromide凝胶后病情出现具临床意义的改善。之前所公布的两项sofpironium bromide临床3期试验的积极结果显示，该药物达成所有主要和次要终点。这两项3期研究共超过700例患者入组，并有约300例患者参加一项为期48周的药物安全性研究。在所有研究中均未发生治疗相关严重不良事件，不良事件为一过性，性质为轻度至中度。活性成分：Ensifentrine适应症：慢性阻塞性肺病（COPD）公司名称：Verona PharmaEnsifentrine是一款潜在“first-in-class”磷酸二酯酶3/4（PDE3/4）抑制剂，双重抑制机理使其能够凭借单个化合物同时实现支气管扩张和抗炎效果。目前美国FDA正在对ensifentrine用以治疗COPD患者的新药申请进行审评。根据新闻稿，如果获批，ensifentrine将成为20多年来首个用于维持治疗慢性阻塞性肺病的新型吸入疗法。该疗法也在今年初被行业媒体Evaluate列为2024有望获批的10款重磅疗法之一。Verona在两项3期临床试验ENHANCE-1和ENHANCE-2中评估了雾化ensifentrine作为维持疗法治疗COPD的效果。Ensifentrine在两项试验中均达到主要终点，患者肺功能获得统计显著和具有临床意义的改善。对ENHANCE-1和ENHANCE-2试验的合并数据分析显示，ensifentrine大幅度降低COPD恶化的风险。▲Ensifentrine化学结构式（图片来源：PubChem）活性成分：Patritumab deruxtecan适应症：非小细胞肺癌（NSCLC）公司名称：第一三共；默沙东Patritumab deruxtecan是第一三共基于其DXd抗体偶联药物平台开发的潜在“first-in-class”HER3靶向抗体偶联药物（ADC），现由第一三共和默沙东共同开发和商业化。美国FDA已受理该疗法用于治疗既往接受过2种或以上系统治疗的局部晚期或转移性EGFR突变NSCLC成人患者的生物制品许可申请，并授予优先审评资格。根据新闻稿，如果获批，patritumab deruxtecan将成为这类患者的首个人表皮生长因子受体3（HER3）靶向抗体偶联药物。该申请主要是基于HERTHENA-Lung01关键2期试验的数据。该开放标签试验在225例EGFR突变的局部晚期或转移性NSCLC患者中开展，这些患者在接受了EGFR酪氨酸激酶抑制剂（TKI）和含铂化疗后发生疾病进展。分析显示，接受patritumab deruxtecan治疗患者的客观缓解率（ORR）为29.8%（95% CI：23.9-36.2），包括1例完全缓解和66例部分缓解，中位缓解持续时间为6.4个月（95% CI：4.9-7.8）。活性成分：Marnetegragene autotemcel适应症：严重I型白细胞粘附缺陷（LAD-I）公司名称：Rocket PharmaceuticalsMarnetegragene autotemcel是一款用以治疗LAD-I的在研基因疗法，该疗法通过慢病毒对患者的自体造血干细胞进行基因工程化改造，以递送ITGB2基因的功能性拷贝。该基因编码β-2整合素成分CD18，这是一种促进白细胞粘附并使其从血管中渗出以抵抗感染的关键蛋白质。该疗法全球1/2期关键研究的更新数据显示，在18至45个月的随访期间，接受marnetegragene autotemcel治疗的全部9名严重LAD-I患者皆展现持续的疗效与安全性。在没有进行造血干细胞移植（HSCT）的情况下，所有9例患者在输注后至少18个月时观察到100%的生存率；所有在入组时年纪小于12个月的患者在没有进行HSCT的情况下，生存时间皆超过了24个月。该试验达到所有主要和次要终点，包含持续的遗传学与表型校正。▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC. Retrieved December 8, 2023, from https://www.ipsen.com/press-releases/ipsen-confirms-u-s-fda-grants-priority-review-for-new-drug-application-for-elafibranor-for-the-treatment-of-rare-cholestatic-liver-disease-pbc/[2] Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS. Retrieved March 15, 2024, from https://ir.geron.com/investors/press-releases/press-release-details/2024/Geron-Announces-FDA-Oncologic-Drugs-Advisory-Committee-Votes-in-Favor-of-the-Clinical-BenefitRisk-Profile-of-Imetelstat-for-the-Treatment-of-Transfusion-Dependent-Anemia-in-Patients-with-Lower-Risk-MDS/default.aspx[3] FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults，Retrieved December 20, 2023 from https://www.businesswire.com/news/home/20231219406441/en[4] BOT: Commercial Day Webinar. Retrieved June 1, 2024 fromhttps://botanixpharma.com/wp-content/uploads/BOT.ASX-BOT-Commercial-Day-Webinar-051324.pdf[5] Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS. Retrieved May 10, 2024 from https://www.veronapharma.com/media/verona-pharma-announces-650-million-strategic-financing-oaktree[6] Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. Retrieved December 22, 2023 from https://www-merck-com.libproxy1.nus.edu.sg/news/patritumab-deruxtecan-granted-priority-review-in-the-u-s-for-certain-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer/[7] Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Retrieved May 10, 2024 from https://www.businesswire.com/news/home/20240510805823/en免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

优先审批临床3期疫苗上市批准申请上市

100 项与 Sofpironium Bromide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10989	-	M03AX	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
原发性腋窝多汗症	日本	Kaken Pharmaceutical Co., Ltd.	2020-09-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多汗症	临床3期	美国	Fresh Tracks Therapeutics, Inc.	2018-09-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03836287 (CARDIGAN 1, FDA_CDER) 人工标引	临床3期	原发性腋窝多汗症	-	SOFDRA	糧築淵簾積淵糧鏇襯餘(蓋膚範襯遞網鏇壓夢壓) = 鹽艱範網鏇膚鬱鏇鏇獵窪餘艱鹹餘夢顧願製壓 (淵繭窪簾壓壓夢糧夢廠 ) 更多	积极	2024-06-18
				Vehicle	糧築淵簾積淵糧鏇襯餘(蓋膚範襯遞網鏇壓夢壓) = 願顧糧願壓糧蓋範夢網窪餘艱鹹餘夢顧願製壓 (淵繭窪簾壓壓夢糧夢廠 ) 更多
NCT03948646 (CARDIGAN 2, FDA_CDER) 人工标引	临床3期	原发性腋窝多汗症	-	SOFDRA	窪鑰願淵衊願繭觸淵鹹(選衊鹹廠窪簾衊艱選蓋) = 憲夢製艱網簾願簾繭觸觸鏇選窪網艱遞淵獵襯 (築繭構獵壓遞鏇選簾範 ) 更多	积极	2024-06-18
				Vehicle	窪鑰願淵衊願繭觸淵鹹(選衊鹹廠窪簾衊艱選蓋) = 艱願積鹹艱鬱網製範鹹觸鏇選窪網艱遞淵獵襯 (築繭構獵壓遞鏇選簾範 ) 更多
NCT03836287 (BBI-4000-CL-301 \| CARDIGAN 1, CTgov)	临床3期	多汗症	350	Sofpironium Bromide Gel, 15% (Active)	蓋廠壓鹽醖衊築顧鏇遞(鬱積憲積築選簾鑰壓鹽): Odds Ratio (OR) = 2.34 (95.0% CI, 1.47 ~ 3.72), P-Value = 0.0004 更多	-	2024-06-06
				Vehicle (Vehicle)
NCT03948646 (BBI-4000-CL-302 \| CARDIGAN 2 \| Cardigan I, CTgov)	临床3期	多汗症	351	Sofpironium Bromide, 15% (Active)	襯簾糧範簾選簾壓壓廠(鏇醖齋顧窪醖獵衊構願) = 鑰鹹繭艱選蓋獵範衊獵廠餘繭構遞簾糧糧糧觸 (蓋願網獵願窪觸憲獵鬱, 鹽糧窪鏇繭鏇蓋選繭蓋 ~ 齋鑰網顧積構願憲醖艱) 更多	-	2024-05-21
				Vehicle (Vehicle)	襯簾糧範簾選簾壓壓廠(鏇醖齋顧窪醖獵衊構願) = 願繭襯構餘窪遞膚簾壓廠餘繭構遞簾糧糧糧觸 (蓋願網獵願窪觸憲獵鬱, 襯獵築餘壓積衊齋繭夢 ~ 齋構顧鑰襯膚顧鹽艱壓) 更多
NCT03627468 (CTgov)	临床3期	原发性腋窝多汗症	300	Sofpironium Bromide Gel, 5% (Gel, 5%)	製鏇遞醖鏇廠鏇襯鏇襯(獵積蓋壓憲鬱鏇簾鬱鹹) = 憲繭構艱艱範淵餘鑰繭鹹簾製構憲積顧選鏇構 (製簾艱願製憲觸簾遞遞, 蓋壓積淵構醖淵鹹襯鬱 ~ 觸積製襯窪夢膚鏇鑰鹹) 更多	-	2023-05-19
				Sofpironium Bromide Gel, 15% (Gel, 15%)	製鏇遞醖鏇廠鏇襯鏇襯(獵積蓋壓憲鬱鏇簾鬱鹹) = 繭範觸夢齋衊鹽鏇衊積鹹簾製構憲積顧選鏇構 (製簾艱願製憲觸簾遞遞, 齋艱製顧廠鹽築壓襯繭 ~ 鏇鏇築願蓋遞遞鏇糧觸) 更多
NCT03785587 (CTgov)	临床2期	原发性腋窝多汗症	21	Sofpironium Bromide Gel, 15%	鏇範膚選構糧蓋襯齋鏇(鑰繭簾鬱觸鏇膚醖顧窪) = 醖繭餘醖構鏇鑰艱鏇願衊夢獵衊艱憲鹽構餘積 (獵鹹襯積襯衊鬱構選夢, 醖選遞範顧簾積衊鹽構 ~ 醖網淵顧選蓋積壓鑰淵) 更多	-	2023-03-14
NCT03948646 (BBI-4000-CL-302 \| Cardigan I, Corporate Publications) 人工标引	临床3期	多汗症	351	Sofpironium Bromide	窪淵淵鬱鬱醖網憲獵鏇(艱選鑰觸製餘夢鑰築願) = 繭醖窪製鹹獵壓積製襯獵遞夢醖鑰鹽願網艱製 (獵窪壓糧廠窪鬱壓製獵 ) 更多	积极	2021-10-07
				Placebo	窪淵淵鬱鬱醖網憲獵鏇(艱選鑰觸製餘夢鑰築願) = 衊觸淵憲齋鑰膚餘醖觸獵遞夢醖鑰鹽願網艱製 (獵窪壓糧廠窪鬱壓製獵 ) 更多
NCT03836287 (BBI-4000-CL-301 \| Cardigan I, Corporate Publications) 人工标引	临床3期	原发性腋窝多汗症	350	Sofpironium Bromide	構蓋簾廠齋廠積獵繭廠(獵願繭簾觸糧窪簾糧願) = 襯鹽積獵選憲壓鏇夢積願觸願憲餘蓋鏇願構窪 (窪觸築構鬱鏇鑰獵艱壓 ) 更多	积极	2021-10-07
				Placebo	構蓋簾廠齋廠積獵繭廠(獵願繭簾觸糧窪簾糧願) = 構窪構廠鑰範蓋窪醖鏇願觸願憲餘蓋鏇願構窪 (窪觸築構鬱鏇鑰獵艱壓 ) 更多